Drugs.com - Clinical Trials

NIH Researchers Discover Novel Class of Anti-Malaria Antibodies

January 3, 2025 -- A novel class of antibodies that binds to a previously untargeted portion of the malaria parasite could lead to new prevention methods, according to a study from researchers at the National Institutes of Health (NIH) published...

Feb 9, 2025 - 21:44
 0
NIH Researchers Discover Novel Class of Anti-Malaria Antibodies
January 3, 2025 -- A novel class of antibodies that binds to a previously untargeted portion of the malaria parasite could lead to new prevention methods, according to a study from researchers at the National Institutes of Health (NIH) published...
Read More

Tags:

Previous Article

Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Ke...

Next Article

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clini...

Related Posts

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation

Axsome Therapeutics Announces Successful Completion and...

Feb 9, 2025  0

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne Therapeutics Receives FDA Fast Track Designation f...

Feb 9, 2025  0

GSK’s B7-H3-Targeted Antibody-Drug Conjugate, GSK’227, Receives US FDA Breakthrough Therapy Designation in Late-Line Relapsed or Refractory Osteosarcoma

GSK’s B7-H3-Targeted Antibody-Drug Conjugate, GSK’227, ...

Feb 9, 2025  0